Two of Australia's leading protein and biologics research facilities at the Australian Institute for Bioengineering and Nanotechnology (AIBN) will come together under the NBF banner. This combines NBF's deep expertise in biopharmaceutical development, clinical manufacturing, and therapeutic translation with the Protein Expression Facility's (PEF) recombinant protein production capabilities across multiple expression systems.

Under the new banner, NBF will offer an end-to-end suite of services, from early-stage recombinant protein production across multiple expression systems and purification through to clinical-grade biologic manufacturing, and will support researchers across academia, industry, and government in bringing next-generation therapeutics, vaccines, and diagnostics to life.

The combined National Biologics Facility and Protein Expression Facility team at the Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland
The unified National Biologics Facility team, bringing together NBF and the Protein Expression Facility at AIBN, University of Queensland.

Modalities supported: monoclonal antibodies, bispecifics, antibody fragments, nanobodies, antibody-drug conjugates, radioligand and radiopharmaceutical precursors, recombinant vaccines, Fc-fusion proteins, therapeutic enzymes, and diagnostic and biomarker proteins.

Expression systems: E. coli, yeast (Pichia), insect (baculovirus), and mammalian.

This is a landmark step for Australia's biologics and biomanufacturing ecosystem, and we look forward to continuing to support our users under our new operating model.